China Crispr And Cas Genes Market Size & Outlook
China crispr and cas genes market, 2018-2030 (US$M)
Related Markets
China crispr and cas genes market highlights
- The China crispr and cas genes market generated a revenue of USD 355.4 million in 2024 and is expected to reach USD 1,162.8 million by 2030.
- The China market is expected to grow at a CAGR of 22.5% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 355.4 million |
| Market revenue in 2030 | USD 1,162.8 million |
| Growth rate | 22.5% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, China accounted for 7.6% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,162.8 million by 2030.
Product was the largest segment with a revenue share of 92.74% in 2024. Horizon Databook has segmented the China crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
China accounted for a significant revenue share in Asia Pacific. As China holds a major share in the agriculture industry, researchers are continuously deploying CRISPR technology in this field. In addition, they are applying genome editing techniques in animals to facilitate human transplantation.
In recent years, China has introduced the largest number of clinical trials involving CRISPR technology in cancer treatment. As of December 2018, China holds 858 publicly available CRISPR patent applications, especially in agricultural and other industries.
Extensive research studies and a large number of patents are expected to drive revenue generation in China’s CRISPR market. In August 2016, researchers from the Sichuan University’s West China Hospital received approval from the hospital’s review board to conduct a CRISPR–Cas9 technique-based gene-editing trial in humans.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China crispr and cas genes market size, by product & service, 2018-2030 (US$M)
China CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
